|
|
 |
|
Viewing report
|
|
 |
5-HT7 antagonists: Novel molecules for the unmet migraine prophylaxis market
Lead Discovery, March 2003
This report offers a 'one stop shop' for personnel involved in the selection, development and commercialization of novel candidates for CNS or cardiovascular disorders, taking readers through multiple aspects of development including target selection/proof of concept, market analysis, the identification of potential competitors and finally an analysis of current pharmaceutical activity in this field. We conclude that 5-HT7 receptor ligands hold considerable potential.
Please view Executive Summary for more details.
|
 |
|
|